N
1.84
-0.20 (-9.80%)
市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 看涨 | 混合的 |
| Biotechnology (全球的) | 看涨 | 混合的 | |
| 股票 | NRX Pharmaceuticals, Inc. | 看跌 | 看涨 |
AIStockmoo 评分
-0.4
| 分析师共识 | 3.0 |
| 内部交易活动 | NA |
| 价格波动 | 0.5 |
| 技术平均移动指标 | -2.5 |
| 技术振荡指标 | -2.5 |
| 平均 | -0.38 |
|
NRX Pharmaceuticals Inc is a clinical-stage, small-molecule pharmaceutical company that develops and plans to distribute novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. It has announced the commercialization of ZYESAMI (Aviptadil), an application for COVID-related respiratory failure. The company is also developing NRX-100/101, the first sequential drug regimen for bipolar depression in patients with acute suicidal ideation and behavior. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 投资方式 | Small Core |
| 内部持股比例 | 15.88% |
| 机构持股比例 | 13.34% |
所有权
| 姓名 | 日期 | 持有股份 |
|---|---|---|
| Anson Funds Management Lp | 30 Sep 2025 | 2,025,104 |
| Advisorshares Investments Llc | 30 Sep 2025 | 342,136 |
| One Wealth Management Investment & Advisory Services, Llc | 31 Dec 2025 | 37,873 |
| Chicago Partners Investment Group Llc | 31 Dec 2025 | 33,421 |
| Sjbenen Advisory, Llc | 31 Dec 2025 | 15,000 |
| Ethos Financial Group, Llc | 31 Dec 2025 | 11,900 |
| 52周波幅 | ||
| 目标价格波幅 | ||
| 高 | 48.00 (Ascendiant Capital, 2,508.70%) | 购买 |
| 中 | 37.00 (1,910.87%) | |
| 低 | 25.00 (BTIG, 1,258.70%) | 购买 |
| 平均值 | 36.75 (1,897.28%) | |
| 总计 | 4 购买 | |
| 平均价格@调整类型 | 2.32 | |
| 公司 | 日期 | 目标价格 | 调整类型 | 价格@调整类型 |
|---|---|---|---|---|
| BTIG | 15 Jan 2026 | 25.00 (1,258.70%) | 购买 | 2.15 |
| 03 Dec 2025 | 25.00 (1,258.70%) | 购买 | 2.41 | |
| D. Boral Capital | 05 Jan 2026 | 34.00 (1,747.83%) | 购买 | 2.41 |
| 03 Dec 2025 | 34.00 (1,747.83%) | 购买 | 2.41 | |
| Ascendiant Capital | 02 Jan 2026 | 48.00 (2,508.70%) | 购买 | 2.62 |
| HC Wainwright & Co. | 16 Dec 2025 | 40.00 (2,073.91%) | 购买 | 2.10 |
该时间范围内无数据。
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合